Status:
RECRUITING
Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)
Lead Sponsor:
University Hospital, Brest
Conditions:
Human Papilloma Virus
Infertility, Female
Eligibility:
FEMALE
25-38 years
Brief Summary
The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health pro...
Detailed Description
This is a single-center prospective study in the assisted reproduction center of Brest University Hospital. All new patients coming to consult will be offered participation in the study. The HPV test ...
Eligibility Criteria
Inclusion
- all etiology of infertility AMH \> ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months
Exclusion
- Age \< 25 y Age \> ou = 38 y AMH \< 1.1 ng/ml patient under juridic protection rejection of participation
Key Trial Info
Start Date :
February 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 4 2026
Estimated Enrollment :
618 Patients enrolled
Trial Details
Trial ID
NCT06550531
Start Date
February 4 2022
End Date
February 4 2026
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609